Adlai Nortye publishes presentation on AN4035 preclinical cancer research
ANL•Adlai Nortye published preclinical results for AN4035, reporting a 100% response rate across five patient-derived tumor models when combined with cetuximab, versus 60% for AN4035 alone. The results support an ongoing Phase I trial in advanced solid tumors with RAS mutations.
1. Preclinical results
Adlai Nortye published a research presentation on AN4035, its CEACAM5-targeted antibody-drug conjugate carrying a pan-RAS(ON) inhibitor. Combined with cetuximab, AN4035 achieved a 100% response rate across five patient-derived tumor models, compared with 60% for AN4035 alone.
2. Toxicity and trial
In monkeys, the combination showed no clear evidence of additive toxicity relative to AN4035 alone, while moderate skin ulceration remained an adverse finding. The results support an ongoing Phase I trial evaluating AN4035 alone or with cetuximab in advanced solid tumors harboring RAS mutations.




